February 2024
1. ZAVESKY L, Jandakova E, Weinberger V, Minar L, et al
   Human endogenous retroviruses (HERVs) in breast cancer: altered expression pattern implicates divergent roles in carcinogenesis.
   Oncology. 2024 Feb 26. doi: 10.1159/000538021.
   

   >> Share

   
   January 2024
2. HADAR M, Friger M, Ariad S, Koretz M, et al
   Stage I Breast Cancer in the Modern Era: A Retrospective Cohort Study of 328 Patients Diagnosed from 2002 to 2006 with a 14- year Median Follow-Up.
   Oncology. 2024 Jan 5. doi: 10.1159/000536119.
   

   >> Share

   
   December 2023
3. CHIANG CH, Chang YC, Haw Y, Tan JY, et al
   The Effect of Exercise on Cardiotoxicity in Women with Breast Cancer Receiving Anthracycline-based chemotherapy: A Systematic Review and Meta-analysis.
   Oncology. 2023 Dec 15. doi: 10.1159/000535737.
   

   >> Share

   
   November 2023
4. SARFRAZ H, Bari S, Whiting J, Sur M, et al
   A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience.
   Oncology. 2023 Nov 27:1-11. doi: 10.1159/000534953.
   

   >> Share

   
   September 2023
5. HE Y, Chen Q, Zhu F, Liu C, et al
   Preoperative radiotherapy does not change the existing treatment paradigm in stage III breast cancer.
   Oncology. 2023 Sep 25. doi: 10.1159/000533858.
   

   >> Share

   
   
6. ZHANG S, Yu X, Xiu Y, Qiao K, et al
   Clinicopathological characteristics of breast cancer patients with HER-2 low expression received neoadjuvant therapy.
   Oncology. 2023 Sep 5. doi: 10.1159/000533787.
   

   >> Share

   
   August 2023
7. LANDRY CA, Blanter J, Ru M, Fasano J, et al
   Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer.
   Oncology. 2023 Aug 18. doi: 10.1159/000533420.
   

   >> Share

   
   
8. KAR S, Niharika, Roy A, Patra SK, et al
   Overexpression of SOX2 Gene by Histone Modifications: SOX2 Enhances Human Prostate and Breast Cancer Progression by Prevention of Apoptosis and Enhancing Cell Proliferation.
   Oncology. 2023 Aug 4:1-18. doi: 10.1159/000531195.
   

   >> Share

   
   July 2023
9. YANG Y, Liu C, Zhuo ZL, Xie F, et al
   Germline mutations in 32 cancer susceptibility genes by Next-Generation Sequencing among breast cancer patients.
   Oncology. 2023 Jul 29. doi: 10.1159/000532095.
   

   >> Share

   
   February 2023
10. DOGAN I, Kizildag I, Ozkurt S, Ibis K, et al
    Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process.
    Oncology. 2023 Feb 21:1-8. doi: 10.1159/000529030.
    

    >> Share

    
    January 2023
11. CANNELLA L, Perri F, Clemente O, von Arx C, et al
    The Complex Management of the Breast Angiosarcoma: A Retrospective Study.
    Oncology. 2023;101:234-239.
    

    >> Share

    
    
12. SUZUKI Y, Kaneko H, Tamura Y, Okada A, et al
    Sex-Specific Differences in the Risk of Heart Failure following Anti-HER2 Monoclonal Antibody Therapy.
    Oncology. 2023;101:358-361.
    

    >> Share

    
    
13. JORGENSEN JT
    The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
    Oncology. 2023;101:836-842.
    

    >> Share

    
    
14. LIU L, Lewis N, Sun W, Whiting J, et al
    Retrospective Study of Treatment Patterns and Natural History of Patients with T1a/b N0 Triple-Negative Breast Cancers: A Single-Institution Experience.
    Oncology. 2023;101:765-772.
    

    >> Share

    
    September 2022
15. SAWA A, Bando H, Kamohara R, Takeuchi N, et al
    Absolute lymphocyte count (ALC) as an independent prognostic factor in metastatic breast cancer: a retrospective study.
    Oncology. 2022 Sep 13. pii: 000526963. doi: 10.1159/000526963.
    

    >> Share

    
    August 2022
16. JAFRI M, Kristeleit H, Misra V, Baxter M, et al
    Eribulin treatment for patients with metastatic breast cancer: The United Kingdom experience - a multicenter retrospective study.
    Oncology. 2022 Aug 31. pii: 000526140. doi: 10.1159/000526140.
    

    >> Share

    
    July 2022
17. CHOI HJ, Lee JH, Jung CS, Lee JE, et al
    Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Oncology. 2022 Jul 26. pii: 000526155. doi: 10.1159/000526155.
    

    >> Share

    
    April 2022
18. NGUYEN V, Chen J, Lord R, Preda V, et al
    The Impact of Multidisciplinary Weight Management on Body Weight and Body Mass Composition in Women with Breast Cancer Post-Adjuvant Chemotherapy: A Retrospective Chart Review.
    Oncology. 2022 Apr 11. pii: 000524519. doi: 10.1159/000524519.
    

    >> Share

    
    March 2022
19. SHIKDAR S, Hall S, Taylor B, de Los Angeles J, et al
    Evaluating the Response of Palbociclib on Progression Free Survival in Hormone Receptor Positive Metastatic Breast Cancer.
    Oncology. 2022 Mar 28. pii: 000524340. doi: 10.1159/000524340.
    

    >> Share

    
    
20. CHAUHAN D, Geetika, Kumar S, Kumar R, et al
    Combined Interaction of Cellular and Extracellular Components Causes Genetic Cascade Activation in Breast Cancer Metastasis.
    Oncology. 2022 Mar 25. pii: 000524302. doi: 10.1159/000524302.
    

    >> Share

    
    February 2022
21. FUJITA N, Fujita K, Kim SJ, Iguchi C, et al
    Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-up of Prognostic Study Using Propensity Score Matching.
    Oncology. 2022 Feb 3. pii: 000522384. doi: 10.1159/000522384.
    

    >> Share

    
    January 2022
22. BILGILIER C, Fureder T, Kastner MT, Vass Z, et al
    Oral Abundance of Actinomyces spp. in Breast Cancer Patients.
    Oncology. 2022 Jan 20. pii: 000522070. doi: 10.1159/000522070.
    

    >> Share

    
    December 2021
23. FABI A, Ciccarese M, Scagnoli S, Russillo M, et al
    Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?
    Oncology. 2021 Dec 7. pii: 000521252. doi: 10.1159/000521252.
    

    >> Share

    
    
24. YAMAGUCHI K, Matsunuma R, Hayami R, Tsuneizumi M, et al
    Comparison of the Modified IHC4 Score and 21-Gene Recurrence Score Assay in Patients with Estrogen Receptor-Positive Breast Cancer.
    Oncology. 2021 Dec 7. pii: 000521287. doi: 10.1159/000521287.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share